Advertisement
Advertisement
ARWR
Arrowhead Research Corporation
75.90
USDSponsored
+0.36
+0.48%
May 22, 11:29 UTC -4
Open
ARWR Earnings Reports
Positive Surprise Ratio
ARWR beat 13 of 41 last estimates.
32%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q3 26 (Revenue/ EPS)
$54.18M
/-$1.39
Implied change from Q2 26 (Revenue/ EPS)
-26.52%
/+49.46%
Implied change from Q3 25 (Revenue/ EPS)
+95.14%
/+10.32%
Arrowhead Research Corporation earnings per share and revenue
On May 07, 2026, ARWR reported earnings of -0.93 USD per share (EPS) for Q2 26, beating the estimate of -1.21 USD, resulting in a 23.20% surprise. Revenue reached 73.74 million, compared to an expected 81.59 million, with a -9.63% difference. The market reacted with a -6.75% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 13 analysts forecast an EPS of -1.39 USD, with revenue projected to reach 54.18 million USD, implying an increase of 49.46% EPS, and decrease of -26.52% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
Satellos Bioscience Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.61
Actual
-$0.53
Surprise
+13.58%
aTyr Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.11
Surprise
+21.60%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
BioXcel Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.49
Actual
-$0.54
Surprise
-9.16%
Cocrystal Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
Outlook Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q2 26
Estimate
-$0.12
Actual
-$0.16
Surprise
-30.72%
Pasithea Therapeutics Corp. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.45
Actual
-$0.12
Surprise
+73.86%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
FAQ
What were Arrowhead Research Corporation's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Arrowhead Research Corporation reported EPS of -$0.93, beating estimates by 23.2%, and revenue of $73.74M, -9.63% below expectations.
How did the market react to Arrowhead Research Corporation's Q2 2026 earnings?
The stock price moved down -6.75%, changed from $77.95 before the earnings release to $72.69 the day after.
When is Arrowhead Research Corporation expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for Arrowhead Research Corporation's next earnings report?
Based on 13
analysts, Arrowhead Research Corporation is expected to report EPS of -$1.39 and revenue of $54.18M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement